| Theme | Amyloid-Related Bone and Joint Derangements -- Clinical Diagnosis and Treatment | |
|---|---|---|
| Title | New diagnostic method of dialysis-related amyloidosis with imagings using 131I and 111In labeled beta2-microglobulin | |
| Publish Date | 1997/08 | |
| Author | Shin Hasegawa | Koseiren Kariwagun General Hospital |
| Author | Fumitake Gejyo | Fukui Medical School, Department of Clinical and Laboratory Science |
| [ Summary ] | New diagnostic imaging modalities using 131I or 111In labeled beta2-microglobulin (beta2-MG) were employed in patients undergoing hemodialysis and continuous ambulatory peritoneal dialysis in order to study their utility in diagnosing dialysis-related amyloidosis (DRA). All participants understood the aim of this study and gave informed consent. The sterilized 131I and 111 In labeled beta2-MG preparations were given intravenously. At 48 hours after the injection, whole body imaging was performed in all patients. Positive images using both tracers were obtained, in the same way, at large joints (shoulders, elbows, wrists, hips, knees and ankles) in patients with biopsy proven amyloid. Furthermore, the images were positive at not only joints in which the patients felt pain or had positive findings on x-ray examinations and in whom amylofd deposits were proved, but also at joints in which they did not. In some patients, positive images were revealed shortly after injection. Negative images were obtained in patients who had secondary hyperparathyroidism, secondary amyloidosis due to rheumatoid arthritis and pseudogout. Imaging using 131I or lll In labeled beta2-MG is potentially useful for diagnosing and estimating the activity indices of DRA, as well as for evaluating the effectiveness of DRA treatment. |
|